Alain CornetHelp us understand the multiple facets of life with lupus today…
Alain CornetSince Hydroxychloroquine (HcQ) has been regularly mentioned in media as a potential medication in the fight against COVID, the number of patients highlighting unavailability issues increased substantially. With the help of its members, LUPUS EUROPE initiated a survey amongst patients to obtain broad based feedback on the magnitude and impact of the issue. Results covering […]
Alain CornetOver the past weeks, LUPUS EUROPE and several of its members have worked to improve availability of Hydroxychloroquine for people with lupus in Europe, as speculations on its possible use for COVID treatment have resulted in an increased (off-label) demand. Our objective is that all patients with a chronic condition requiring Hydroxychloroquine have access, if […]
Alain CornetLUPUS EUROPE and the ERN ReCONNET Patient representatives have launched a short survey to better understand how we can improve quality of life for people living with a rheumatic condition through better patient education. If you are a patient living with a Rheumatic condition or any other Chronic or rare disease, simply follow this link […]
Alain CornetDid you know? Lupus is a Rare Disease! Lupus is rare, but not for us! Come and join us working on our vision: A fulfilling life for all people with Lupus in Europe until we have reached a world without Lupus What is a rare disease? It changes from country to country, but in Europe […]
Alain CornetWe are very proud to announce that LUPUS EUROPE has been recognized by the EMA (European Medicine Agency) as “eligible entity”, the select network of patient organizations that work with the EMA to ensure that the needs and concerns of a wide range of patients are represented via direct contact with the Agency. This status […]
Alain CornetWe would very much like to share some news with you! If you are a Lupus Europe member or potential member, volunteer or potential volunteer, or simply a member of the patient community interested in the activities of LUPUS EUROPE, join us on February 17, 2020 at 20:00 Paris time. On the agenda:– Introduction of […]
As part of its cooperation with the ERN ReCONNET, Lupus Europe is launching an important survey, which we would like to ask you to disseminate as largely as you can to people actually living with lupus. We have made the effort of providing 13 different languages, and are open to adding new ones, so we hope […]
Alain Cornet30 Years ago, on May 26, 2019, LUPUS EUROPE’s Constitution (then under the name of ELEF) was signed… The European Lupus Federation was born. as we celebrate this anniversary, we asked current and past Chairs to reflect on those years in support of People living with lupus in Europe. Yvonne Norton, Chair from 2002 […]
Alain CornetThe 22nd EULAR Annual European Conference of PARE took place in the stunning, historical city of Prague in the Czech Republic 5-7 April 2019 with over 120 delegates. PARE ‘People with Arthritis and Rheumatism in Europe’ forms an integral role at EULAR ‘The European League Against Rheumatism’. The presentations and workshops at the PARE Conference […]
📣 #meetthespeakers! We are delighted to have Prof. Marta Alarcón-Riqueleme from @genyo_pts as a speaker @ConferenceEfi, #plenary session IV "#ai & big data transforming medical research"
Don't miss her talk👇
@3TR_IMI @twit_PAG @soumya_boston @yluo86 @jillahjillah @So_Limou https://twitter.com/ConferenceEfi/status/1640685435599896577
📢 #EFI2023 PLENARY SPEAKER ANNOUNCEMENT!
Meet Prof. Marta Alarcón-Riquelme 👏
She will speak about: "Using transcriptome data to stratify and predict treatment responses in lupus and other systemic autoimmune diseases"
Reserve your spot 👉 https://lnkd.in/eFWEtXq7
✅ In #PANLAR2023, I will give a talk about "10 pearls in #Lupus". My pearl #1 ⬇️ is that there is an ongoing debate about the optimal daily dose of #hydroxychloroquine in #SLE. My point of view is that it's a trade-off between efficacy and eye 👁️ toxicity.
➡️ What do you think?
Proud to see some of our PAN members in the @eupatients Patient Expert Training Programme!
Best of luck to all the trainees!
Exciting day as our 105 trainees attend the Patient Expert Training Programme online event😍
Over 4 days our #Cohort6 will get to know each other & continue to study together 🤓
Fantastic start this morning & best of luck with your studies 🙏
#IAmEUPATIFellow #OpenClassroom
More answers needed from patients!
Please share so that it can reach more people 🙏 .
Thank you!
@chriswincup @Cambridge_Uni The new INSPIRE survey can be completed by lupus patients or their carers from around the world. Please share as much as possible in order to get a sample that includes a good proportion of all ethnic groups. Thank you!
https://bit.ly/inspire_patients_short
🚨 Call for patients🚨
🔊 INSPIRE SURVEY from the University of Cambridge.
This survey aims to improve the understanding of neurological symptoms in SLE and other rheumatic conditions.
Lupus is a very heterogeneous disease, which means that it affects people of different ethnic backgrounds and gender in different ways.
That is why, to get accurate research results, as many different groups as possible must be represented in the sample.
The INSPIRE survey was launched last year to get the patient experience on the assessment/monitoring of neurological symptoms, but they received very few responses from people from ethnic minorities.
That is why the research team led by Dr Chris Wincup has launched a new survey.
The new INSPIRE survey can be completed by lupus patients or their carers from around the world.
🟣 Please share as much as possible 🟣 in order to get a sample that includes a good proportion of all ethnic groups.
Thank you!
bit.ly/inspire_patients_short
I did it a second time and no it went good till the end
The survey was demolished.
Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus erythematosus. It is characterised by persistent scaly plaques on the scalp, face, and ears, which can progress to scarring, atrophy, depigmentation, and permanent hair loss in affected hair-bearing areas (Source: DermNet).
This study, published by Prof Marca Mosca et al., describes 2 cases of severe and refractory DLE successfully treated with anifrolumab, a human monoclonal antibody.
Although anifrolumab has been recently approved for the treatment of SLE, data from randomized clinical trials have shown a significant difference in cutaneous response rate in patients treated with anifrolumab from those in the placebo group.
While the effectiveness of this treatment in real life and in different types of skin lesions has yet to be determined, it could represent a new valid opportunity for treating DLE.
jamanetwork.com/journals/jamadermatology/article-abstract/2798967
We know some of you missed the great seminar recently delivered by Prof. Laurent Arnaud.
Well, no worries!
You have the chance to see it again, thanks to the European Federation of Internal Medicine (EFIM).
"Challenges in 2023 for Systemic Lupus Erythematosus".
Next 29th of March at 18:00 CET (i.e. Paris time).
Register for free here!
us02web.zoom.us/webinar/register/WN_O5yMwjfgTS29pMKvOZfgZw
Did you miss this ERN RECONNET webinar with Lou Kawka and Prof Laurent Arnaud about #fatigue in #SLE?
Now you have the chance to watch it!!! 😃🙌
www.youtube.com/watch?v=7jc7SiP5BsA
